pharma
7 stories tagged "pharma"
Anti-Tau Alzheimer's Drugs Keep Hitting Their Target and Missing the Disease
Tau is the new headliner at the Alzheimer's conference, but the anti-tau antibodies keep proving they bind the protein while doing nothing for patients. The clearest win so far is a blood test.
InvestigationsNEJM Retracted the Study That Approved Amgen's Vasculitis Drug. It Had Never Done That in 200 Years.
The FDA says the drug's superiority result came from re-scoring nine patients after the trial was unblinded. It is still on U.S. shelves while Amgen fights the withdrawal.
Metabolic & WeightYour Kidneys Are Quietly Failing. The WHO's Plan Skips What's Actually Killing Them.
The Lancet is pushing fast implementation of the first WHO kidney resolution, which expands screening and treatment access while leaving the ultraprocessed food and sugar driving the global CKD doubling untouched.
Drugs & FDAMedicare's Product-Hopping Loophole Is Back On The Chopping Block. The Bigger Pharma Giveaway Isn't.
The Trump administration on Thursday proposed closing the product-hopping loophole that lets drugmakers reset Medicare's negotiation clock by tweaking inactive ingredients. It is the same fix the same administration quietly tabled in October.
CancerOzempic's 30 Percent Breast-Cancer Headline, and the Trial Evidence It Walked Past
A single-system observational study at ASCO 2026 attached a roughly 30% lower breast-cancer rate to GLP-1 use. The randomized record already on the table is quieter.
Metabolic & WeightA gut hormone keeps showing up in the brain's reward circuit, and 600,000 veterans just gave us the biggest hint yet that it matters
A VA cohort of 606,000 diabetic veterans on GLP-1 drugs showed lower risks of new substance use disorders and large drops in overdose and drug-related death versus a peer diabetes drug. The mechanism story is where it gets interesting.
Drugs & FDAAlnylam Bet $2 Billion on AI-Designed RNAi. The Check It Actually Wrote Was $30 Million.
Alnylam paid Inceptive Nucleics $30 million up front, with up to $2 billion in milestones tied to outcomes the rest of AI drug discovery has spent a decade failing to deliver.